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Neonatal Episodic Hypoglycemia: 




Epilepsy is common and has a prevalence of 5.25 per
1000. One third of epilepsy patients are women of reproduc-
tive age. Most women with epilepsy require ongoing 
antiepileptic drug (AED) therapy during pregnancy. Both 
seizures during pregnancy and AED exposure in utero are
thought to affect the poor outcomes seen in babies born to
epileptic mothers (1). In utero, AED exposure may cause
congenital malformations and may also lead to withdrawal
symptoms in the newborn (1-5). We present here a 
newborn patient with withdrawal symptoms due to valproic
acid (VPA) and phenytoin (PH) exposure in utero.
Case Report
A male infant was born at 35 weeks gestation by 
caesarean section because of placenta previa. He had 
bradycardia and difficulty in breathing, requiring resuscitation.
The 21-year-old mother had complex partial epilepsy and
was treated with PH (200 mg/day) and VPA (600 mg/day).
The patient was the third child of non-consanguineous 
parents. The mother had undergone three abortions. The
baby’s weight was 2720 g, length 56 cm, head circumference
36.5 cm. Physical examination revealed cyanosis, intercostal
retractions, tachypnea, and hypotonia. Laboratory findings
were as follows: Hemoglobin: 18.9 g/dL, WBC: 20800 mm3/L,
PLT: 114 000 mm3/L, AST: 139 IU/L (N: 0-40), ALT: 34 IU/L
(N: 0-40), CPK:3233 IU/L (N: 40-226 IU/L), CPKMB:380 IU/L
(N: 2-20 IU/L) LDH: 2152 IU/L (N: 100-190 IU/L). Other 
laboratory studies, including blood glucose levels, did not 
reveal any abnormality. 
ABSTRACT
The treatment of epilepsy during pregnancy is a worldwide problem.
Drugs need to be used to control seizures in the mothers. In utero, 
exposure to valproic acid (VPA) and phenytoin (PH) may cause 
congenital malformations and also withdrawal symptoms such as 
irritability, jitteriness and symptoms of hypoglycemia. We present here
a newborn with episodic hypoglycemia due to in utero exposure to VPA
and PH. The mother was diagnosed as having complex partial epilepsy
and was treated with PH (200 mg/day) and VPA (600 mg/day). The 
offspring developed jitteriness on the second day of life. The infant was
hypoglycemic (32 mg/dl). These findings were accepted as withdrawal
symptoms, since serum levels of VPA and PH were 37.8 μg/ml (50-100
μg/ml) and 6.37 μg/dl (10-20 μg/ml), respectively. Measurement of
blood glucose is important and should be carefully monitored in infants
exposed to antiepileptics in utero.
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and head box oxygen and fluid repletion were initiated. His
vital functions normalized, but he developed jitteriness on
the second day of life. Laboratory investigations revealed
hypoglycemia (32 mg/dL) and IV glucose infusion was 
initiated. Because his mother took VPA and PH for her 
epilepsy, the baby was evaluated for withdrawal symptoms
and blood drug levels were analyzed. VPA level was 37.8
μg/mL (normal levels 50-100 μg/mL) and PH level was 6.37
μg/dL (normal levels10-20 μg/mL) and were measurable, 
although none of these were used in the offspring. 
Following the IV glucose infusion, the blood glucose level
became normal and the jitteriness disappeared. Oral 
feeding was started with gradual reduction of the infusion
rate. Hypoglycemia was observed again on the sixth day 
(38 mg/dL). IV treatment was continued until the 10th day of
life, when oral feedings were fully initiated. Hypoglycemia did
not recur and the patient was discharged. 
Discussion
The optimal management of epileptic women during
their childbearing years and, particularly during their 
pregnancies, presents a considerable clinical dilemma. It
has been recognized that treatment with AED during 
pregnancy is related to an increased risk for major congenital
malformation. However, the justification for treatment has
been that the risks of seizures during pregnancy are greater
than those of AED therapy (1). Maternal death rate is 
approximately 10 times higher in women with epilepsy than
in the general population. The death histories in the reports
include seizure occurrence often associated with stopping
AED or with poor compliance. There is little data regarding
risk for malformations or other adverse outcome in the 
fetus as a result of seizures (6). Major and minor congenital
anomalies have been reported to occur with most AEDs,
including carbamazepine, PH, and VPA (7). 
A number of adverse effects, including teratogenesis, 
liver toxicity and weight gain have been reported with VPA
treatment  (2,4-9). Long-term VPA treatment can cause 
carnitine deficiency (2,10). VPA is 80 to 90% bound to 
plasma proteins. VPA crosses the placenta and is found in
higher concentrations in cord serum than in maternal serum
(2,11). It is metabolized by the liver (2). Nau et al (12)
showed that VPA is excreted in the newborns with a mean
half-life of 47±15 hours, this duration being approximately 4
times the mean value found in adult epileptics. Meador et
al  (13) showed that the highest overall incidence of 
malformations occur in pregnancies exposed to VPA. When
AEDs were compared in monotherapy groups, VPA 
continued to show the highest incidence of malformed
births.
The most frequent major congenital malformations 
occurring with AEDs are neural tube defects, congenital 
heart defects, oral clefts, genital abnormalities, and limb 
defects (2,5,14,15). In fetuses exposed to VPA, neural tube
defects occur 10 times higher than the normal incidence
and appear to be specifically associated with VPA therapy
rather than with other antiepileptics (2). Effects on major 
organ systems are expected to occur with first trimester 
exposure and with maternal doses of over 1000 mg a day
(2,8,14,15). More recently there has been concern about a
possible increased risk of neurodevelopmental problems in
children with VPA exposure. Neurodevelopmental effects
are more likely to be due to exposure later in the pregnancy,
when brain cells are proliferating and migrating. 
Developmental milestones are often delayed in these 
children, particularly in the area of speech. Learning and 
behavioral abnormalities show a higher incidence in these
children compared to normal children (1,6,14). Koch et al
(16) reported cerebral dysfunction in children exposed to
VPA in utero. Our patient’s mother was on 600 mg/day VPA
and 200 mg/day PH for five years. Our patient will be 
followed for any neurodevelopmental aberrations. 
PH is another drug widely used for different types of
epilepsy. It is metabolized in the liver. In utero, exposure to
PH may lead to congenital anomalies which are described
as the fetal hydantoin syndrome. This syndrome includes
microcephaly, growth retardation, dysmorphic face, orofacial
clefts, cardiac defects and distal digital hypoplasia with
small nails (3,8,12). Although exposed to PH in utero, our
patient did not have any of these abnormalities. 
Withdrawal signs of AED are also very important in the
neonatal period. In newborns, the signs of withdrawal are
irritability, jitteriness, abnormal tone, seizures, feeding 
problems and hypoglycemia. The signs occur at birth
(3,4,8,15,17). Our patient had jitteriness and hypoglycemia.
Hypoglycemia appears during the first few hours after birth,
but may also occur in the first few days (4). Usually 
hypoglycemia is detected between 12 and 48 hours after
birth and is dose-related (2,15) Hypoglycemia in these 
babies is more common than in infants of diabetic mothers
(4). Ebbesen et al (4) have suggested that hypoglycemia can
be episodic. During episodes of hypoglycemia, ketone 
bodies originate from fatty acids and may be an alternative
substrate for cerebral metabolism, but VPA inhibits this 
ketogenesis. Thus, hypoglycemia in infants exposed to VPA
in utero may be hypoketotic. Additionally, VPA inhibits 
gluconeogenesis and mitochondrial ß-oxidation of fatty
acids. Thus, hypoglycemia in VPA exposed infants results
from decreased gluconeogenesis and reduced liver 
glycogen and/or impaired glycogenolysis (4). Transient mild
elevations of ALT, AST and LDH were found in children on
VPA monotherapy (18,19). Both VPA and PH may increase
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development is frequently seen in infants exposed to VPA
in utero. Unrecognized hypoglycemia may will be one of the
reasons leading to impaired psychomotor development in
these children (4). PH exposure in utero may cause 
withdrawal symptoms, but it generally induces hyperglycemia
by inhibiting the release of insulin as a result of the 
blockage of calcium uptake via voltage-dependent calcium
channels (21). We detected two cases of hypoglycemia in
PH-exposed infants in the relevant literature. The attempt
to escape from the inhibitory effects of PH on insulin 
secretion or the increased sensitivity of the tissues to 
insulin were suggested as possible mechanisms leading to
hypoglycemia (21,22). However, hypoglycemia is a rare ma-
nifestation of PH exposure and VPA is more potent than PH
in carbohydrate metabolism. 
In conclusion, infants exposed to VPA have greater risk
for hypoglycemia during the first week and especially in the
first two days of life. Repeated episodes of hypoglycemia in
these infants are reported in the literature. We recommend
that blood glucose should be carefully monitorized in these
infants, particularly in the first two days after birth. 
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